Employees: 2,252
Size Anhui Huaheng Biotechnology (688639.SS) is a China Health Care company (Biotechnology) with a market value of $605M, the 3220th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥14.90 on 18 Nov 2026.
Performance Over six months the shares fell 45.0%, against -22.0% for the median peer and -20.0% for the China market (cap-weighted) — 4th lowest of 20 in its peer set.
Growth Revenue grew 7.5% over the last twelve months (peer median +23.1%); the operating margin is 3.5% (peer median -111.2%).
Valuation It trades at 22.3× forward earnings against a peer median of 21.6× (4th cheapest of 7).
Capital Return on invested capital runs 2.3 points below its cost of capital (7.6% WACC).
Next results Next results expected around 28 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥3.04B | CN¥2.86B | CN¥2.18B | CN¥1.94B | CN¥1.42B |
| Revenue growth | — | +31% | +12% | +37% | — |
| Gross profit | CN¥766M | CN¥560M | CN¥511M | CN¥756M | CN¥533M |
| EBITDA | n/a | CN¥368M | CN¥330M | CN¥589M | CN¥376M |
| Net income | CN¥96.1M | CN¥132M | CN¥190M | CN¥449M | CN¥320M |
| Free cash flow | -CN¥397M | -CN¥531M | -CN¥724M | -CN¥965M | -CN¥90.3M |
| Capital expenditure | CN¥563M | CN¥637M | CN¥924M | CN¥1.27B | CN¥456M |
| Total debt | CN¥2.47B | CN¥2.10B | CN¥1.58B | CN¥1.30B | CN¥91.2M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688639.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -17.0% | -15.3% | 10th lowest of 21 |
| 6-month return | -45.0% | -22.0% | 4th lowest of 20 |
| Distance from 52-week high | -65.8% | -46.1% | 5th lowest of 21 |
| Revenue growth (TTM) | +7.5% | +23.1% | 7th lowest of 17 |
| Operating margin | 3.5% | -111.2% | 5th highest of 17 |
| Forward P/E | 22.3× | 21.6× | 4th cheapest of 7 |
| ROIC minus cost of capital | -2.3 pp | -15.2 pp | 4th highest of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Anhui Huaheng Biotechnology 688639.SS | China | $605M | -45% | +7% | 3% | 22.3× | n/a | n/a |
| Surrozen SRZN | United States | $605M | +17% | +192% | -485% | n/a | n/a | n/a |
| Design Therapeutics DSGN | United States | $606M | -15% | n/a | n/a | n/a | n/a | n/a |
| Alebund Pharmaceuticals (Jiangsu) 9637.HK | Hong Kong | $595M | n/a | +674% | -495% | n/a | n/a | n/a |
| Getein Biotech 603387.SS | China | $625M | -13% | +8% | 21% | n/a | -8.9% | -1.3% |
| Janux Therapeutics JANX | United States | $631M | -28% | +133% | -599% | n/a | n/a | n/a |
| Shenzhen Weiguang Biological Products 002880.SZ | China | $633M | -27% | 0% | 18% | 19.2× | n/a | n/a |
| 4D Molecular Therapeutics FDMT | United States | $578M | +23% | +79,952% | -226% | n/a | n/a | n/a |
| Geron GERN | United States | $638M | -21% | +19% | -8% | 17.4× | n/a | n/a |
| Ascletis Pharma 1672.HK | Hong Kong | $571M | -72% | -59% | -71,976% | n/a | n/a | n/a |
| Genfit GNFT.PA | France | $571M | +22% | +28% | -130% | 431.5× | 39.8% | +143.5% |
| Boji Medical Technology 300404.SZ | China | $561M | -6% | +32% | 4% | 69.3× | 31.9% | +27.2% |
| Shouyao Holdings Beijing 688197.SS | China | $653M | -26% | +4,564% | -92% | n/a | n/a | n/a |
| Frontier Biotechnologies 688221.SS | China | $658M | -48% | +153% | -20% | n/a | 40.3% | +21.5% |
| Sana Biotechnology SANA | United States | $554M | -41% | n/a | n/a | n/a | n/a | n/a |
| Hvsen Biotechnology 300871.SZ | China | $553M | -22% | +2% | 17% | 11.7× | n/a | n/a |
| Alphamab Oncology 9966.HK | Hong Kong | $666M | -38% | -32% | -38% | 24.0× | n/a | n/a |
| Steminent Biotherapeutics 7729.TWO | Taiwan | $668M | +292% | n/a | n/a | n/a | n/a | n/a |
| Wave Life Sciences WVE | United States | $546M | -55% | -35% | -321% | n/a | n/a | n/a |
| Climb Bio CLYM | United States | $546M | -12% | n/a | n/a | n/a | n/a | n/a |
| Kura Oncology KURA | United States | $674M | -29% | -24% | -394% | n/a | n/a | n/a |